| __timestamp | Amicus Therapeutics, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 49315000 |
| Thursday, January 1, 2015 | 47269000 | 75043000 |
| Friday, January 1, 2016 | 71151000 | 83749000 |
| Sunday, January 1, 2017 | 88671000 | 122682000 |
| Monday, January 1, 2018 | 127200000 | 207761000 |
| Tuesday, January 1, 2019 | 169861000 | 284812000 |
| Wednesday, January 1, 2020 | 156407000 | 317875000 |
| Friday, January 1, 2021 | 192710000 | 282660000 |
| Saturday, January 1, 2022 | 213041000 | 451421000 |
| Sunday, January 1, 2023 | 275270000 | 481871000 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Sarepta Therapeutics, Inc. and Amicus Therapeutics, Inc., from 2014 to 2023. Over this period, Sarepta's SG&A expenses surged by approximately 878%, reflecting its aggressive expansion and strategic investments. In contrast, Amicus saw a more modest increase of around 1,229%, indicating a steady growth trajectory. Notably, in 2023, Sarepta's expenses peaked at nearly double those of Amicus, highlighting its larger scale of operations. This trend underscores the differing strategies of these companies in navigating the biotech landscape. As the industry evolves, monitoring such financial metrics will be key to understanding the dynamics of growth and sustainability.
Comparing SG&A Expenses: BeiGene, Ltd. vs Amicus Therapeutics, Inc. Trends and Insights
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alkermes plc and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. or Vericel Corporation: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Amicus Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Mesoblast Limited
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.